Jim Cornall

Base to Base Biotech

Health EN ↓ 85 episodes

The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed. The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall. Base to Base is an Ayr Coastal Media Ltd production.

Be sure to visit the podcast's website and support the creator: www.deeptechdigest.com

Author

Jim Cornall

Category

Health

Podcast website

www.deeptechdigest.com

Latest episode

Nov 20, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Base to Base biotech podcast 85: Endometriosis – diagnosis and treatments 20.11.2026

The conversations this week are both related to endometriosis: on developing a new diagnosis tool with San Francisco company Endometrics’ CEO and co-founder Yana Aznavour, and on the developing a treatment side, it’s a discussion with Swedish company Gesynta Pharma’s chief medical officer and VP of clinical development, Eva Johnsson. Times: 03:23 Endometrics 23:15 Gesynta Pharma Endometrics The di...

Base to Base biotech podcast 84: 3D printing and secretomes 13.11.2026

This week, we have a conversation with Dylan Yeo, CEO and co-founder of Klona Biotech about 3D printing of regenerative implants, and we chat with Joana Correia, CEO, CSO, and co-founder of Exogenus Therapeutics, about a new consortium leading the way on secretomes. Times: 03:28 Klona Biotech 25:30 Exogenus Therapeutics Klona Biotech Klona is developing the first bioprinting system specifically de...

Base to Base biotech podcast 83: Different approaches to beating cancer tumours 06.11.2026

Times: 03:22 Ona Therapeutics 24:08 Actuate Therapeutics This week, we have a conversation with Valerie Vanhooren, CEO and co-founder of Ona Therapeutics about first-in-class ADCs for tackling tumours, and Daniel Schmitt, president and CEO of Actuate Therapeutics, about targeting multiple molecular pathways in cancer that are involved in promoting tumour growth. Ona Therapeutics Ona Therapeutics h...

Base to Base biotech podcast 82: Restoring blood flow to the heart and tackling HHT 30.10.2026

This week, we have a conversation with Philip Brainin, CEO of Isomab, about restoring blood flow to the heart, and with RougeTx CEO Andrew Lightfoot, about developing a treatment for hereditary haemorrhagic telangiectasia (HHT). Times: 03:34 Isomab 25:29 RougeTx Isomab Isomab , a preclinical UK biotech, recently presented safety data at ESC recently that may not sound particularly exciting at firs...

Base to Base biotech podcast 81: Breakthrough in shrinking tumours and restoring mitochondrial metabolism to address obesity 23.10.2026

This week, we talk about mitochondria and obesity with Jon Rees, co-founder and CEO of MitoRx Therapeutics, and also have a chat with Apeximmune Therapeutics’ CEO and founder Li-Fen Lee, and senior director of biology Kan Lu, about a new breakthrough in shrinking tumours. Times: 03:11 MitoRx Therapeutics 25:06 Apeximmune Therapeutics MitoRx Therapeutics MitoRx Therapeutics is developing new treatm...

Base to Base biotech podcast 80: Targeting tumour acidity, and developing allosteric therapies 16.10.2026

This week, we chat with Ryan Beal, a cancer survivor and founder and CEO of Dyve Biosciences, about tumour acidity, and Gene Mack, president and CEO of Gain Therapeutics, about developing allosteric therapies, including taking Parkinson’s disease treatments beyond addressing symptoms. Times: 03:03 Gain Therapeutics 25:48 Dyve Biosciences Gain Therapeutics Gain Therapeutics is developing next-gener...

Base to Base biotech podcast 79: Fragile X syndrome and Parkinson’s disease 09.10.2026

This week, we chat with Simon Mølgaard, co-founder and chief executive officer of Teitur Trophics about results from its Parkinson’s disease trial, and have a conversation with Jordi Fàbrega, co-founder and CEO of CONNECTA Therapeutics, and Josep Prous, co-founder and chief scientific officer, about Fragile X syndrome. Times: 03:15 Teitur Trophics 14:03 CONNECTA Therapeutics Teitur Trophics Teitur...

Base to Base biotech podcast 78: A new treatment for erectile dysfunction, and nanotechnology for knee osteoarthritis 02.10.2026

This week, we chat with Lucas Decuypere, CEO and president of Allegro, about treatment of knee osteoarthritis with a nanotechnology injection, and Elin Trampe, the CEO of Dicot Pharma, a company developing a new form of erectile dysfunction treatment. Times: 01:46 Dicot Pharma 17:21 Allegro Allegro Allegro is a Belgium-based biomedical company which recently announced statistically significant imp...

Base to Base biotech podcast 77: Transferring mammal traits to humans, and is injecting tumours a new way to kill cancer? 25.09.2026

This week, we chat with Evan Appleton, chief scientific officer and co-founder of Intertwined, a company focused on understanding mammalian evolved protective traits, and how they can be transferred to humans. And we chat with Lew Bender, CEO of Intensity Therapeutics, which is pioneering an intratumoral injection therapy primarily for breast cancer that not only kills the cancer cells in the tumo...

Base to Base biotech podcast 76: Early disease detection and beating CNS cancers 18.09.2026

This week, we have conversations with Marc Hedrick, CEO of Cerenome, about a combined approach to tackling central nervous system (CNS) cancers, and Shaun Holt, CEO of Alveo Technologies, about the potential for animal diseases to jump to humans, and what we can do about it. Times: 03:27 Cerenome 28:27 Alveo Technologies Cerenome Cerenome , formerly known as Plus Therapeutics, is a central nervous...

Base to Base biotech podcast 75: AI-powered diagnostics and cancer immunotherapy 11.09.2026

Times: 03:17 Asgard Therapeutics 32:43 Waiv This week, we talk to a company in Lund, Asgard Therapeutics, and its co-founder and CEO Cristiana Pires, about in vivo direct cell reprogramming for cancer immunotherapy, and we chat about clinical diagnostics with Meriem Sefta, CEO of Waiv. Asgard Therapeutics Asgard Therapeutics is a biotech pioneering in vivo direct cell reprogramming for cancer immu...

Base to Base biotech podcast 74: A vision for vision, and studying pancreatic cancer 04.09.2026

This week, our guests are Bryan McClellan, who conducted research on pancreatic cancer as a postdoctoral fellow at Dell Medical School, and William Matsui, the study's senior author and former executive vice dean for research at Dell Medical School; and Theialife president and CEO, Thomas Ruggia, about myopia. 02:26 Theialife 27:38 University of Texas Theialife Theialife is a global ophthalmology...

Base to Base biotech podcast 73: Polymacrocyclic peptides and AI in drug discovery and diagnosis 28.08.2026

This week, our guests are chief scientific officer of Valo Health, Karin Conde-Knape, and Karsten Eastman, CEO of Sethera Therapeutics. Times: 03:06 Sethera Therapeutics 20:08 Valo Health Valo Health Our guest from Valo Health is chief scientific officer Karin Conde-Knape. As head of global drug discovery at Novo Nordisk, she helped expand the company’s research pipeline to more than 100 programme...

Base to Base biotech podcast 72: Cell-free DNA bioproduction 21.08.2026

This week, we have a conversation about the Flexible Automation for Scalable Health (FLASH) programme, focused on the development of scalable cell-free DNA bioproduction capabilities. Our guests are John Schiel, program manager at ARPA-H; DNA Script co-founder and CTO, Xavier Godron; and John Nelson, senior biosciences principal and FLASH program lead at GE HealthCare’s Healthcare Technology and I...

Base to Base biotech podcast 71: The IgA/CD89 axis 14.08.2026

This week, we have a conversation Paweł Szczepański, CEO of JJP Biologics about specially-built antibodies to tackle autoimmune diseases and cancer. JJP Biologics JJP Biologics is a clinical-stage biotech that leverages its in-depth understanding of immune pathway science in autoimmune diseases and cancer. Starting from deep mechanistic insights, JJPBio engineers antibodies that are built-to-order...

Base to Base biotech podcast 70: Taking the lead on GI motility disorders 31.07.2026

This week, we have a conversation with Peter G. Milner, founder and director of Renexxion, about GI motility disorders. Renexxion Renexxion, Inc. is a privately held US-headquartered clinical-stage biopharmaceutical company, with a subsidiary in Ireland, committed to developing new therapies for patients with gastrointestinal disorders. Renexxion ’s lead program is naronapride, a late-stage drug c...

Base to Base biotech podcast 69: nrHSV-1 technology and environmental testing through hair 24.07.2026

Times: 01:33 Cyllene Tx 21:37 LinusBio This week, we have conversations with LinusBio founder and Mt. Sinai environmental professor, Dr. Manish Arora, as well as with Philippe Chambon, CEO of Cyllene Therapeutics (Cyllene Tx). Cyllene Therapeutics Cyllene Therapeutics is a global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology. It is currently executing a phase 1/2 study i...

Base to Base biotech podcast 68: Water from air for pharma and beyond 17.07.2026

This week, we have a conversation with Kyle Cordova, founder and CEO of AquaPoro. AquaPoro AquaPoro is a deeptech company engineering systems that can harvest water from the atmosphere based in California that was spun out of Jordan's Royal Scientific Society. Atmospheric water generators (AWGs) aren't uncommon as freshwater becomes scarcer for use in a variety of industries from food and beverage...

Base to Base biotech podcast 67: Synthetic DNA and crossing the blood-brain barrier 10.07.2026

Times: 02:58 Deep Science Ventures 22:16 4basebio This week, we have a conversation with Amy Walker, CEO of 4basebio, and Adam Tomassi-Russell, senior director, climate, at Deep Science Ventures. 4basebio 4basebio is a UK-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4ba...

Base to Base biotech podcast 66: The future of clinical trials and breakthroughs in molecular testing 03.07.2026

This week, we have a conversation with Jeff Fischer, president of Longhorn Vaccines & Diagnostics, and with Hannah Amies, founder and CEO of Luvida. Times: 03:03 Longhorn Vaccines and Diagnostics 25:03 Luvida Longhorn Vaccines & Diagnostics on breakthroughs in molecular testing Maryland-based Longhorn Vaccines and Diagnostics is a IND-enabling stage biopharmaceutical company developing vac...

Base to Base biotech podcast 65: Giving medicine a genetic camouflage 26.06.2026

This week, we have a conversation with Houdini Bio CEO and co-founder Jonathan Cohen-Gold. Houdini Bio has announced its official launch, having raised approximately £1.5m in non-dilutive grant funding and capital from an oversubscribed pre-seed round. The funding enables Houdini Bio to validate its technology and achieve projected technical milestones in a third of the predicted time. The platfor...

Base to Base biotech podcast 64: Solving logistics challenges 19.06.2026

This week on Base to Base, we have a conversation with Bora Pharmaceuticals’ chief commercial officer Jean-Baptiste (JB) Agnus. Bora Pharmaceuticals Bora Pharmaceuticals is an international contract development and manufacturing organization (CDMO) specialising in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics...

Base to Base biotech podcast 63: Cell and gene therapy logistics, and turning back the Parkinson’s clock 12.06.2026

This week, we have a conversation with Mark Sawicki, president and CEO of Cryoport Systems, and we chat with Nick Manusos, CEO of Kenai Therapeutics. Times: 03:22 Cryoport Systems 22:24 Kenai Therapeutics Cryoport Systems Cryoport Systems provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of sensiti...

Base to Base biotech podcast 62: A new approach to strokes 05.06.2026

This week, we have a conversation with Revalesio president Greg Archambeau about tackling strokes, and other conditions, with a novel method. Revalesio While the pharmaceutical industry often focuses on complex chemical compounds, Revalesio is pioneering a novel drug class rooted in a surprising field: fluid physics. Revalesio is also focusing on stroke, a condition in need of new therapies. Reval...

Base to Base biotech podcast 61: Making tumours visible, and taking on tough challenges 29.05.2026

This week, we speak with John Friend, CEO of Kazia Therapeutics; and have a conversation with PureTech Health CEO Robert Lyne and Eric Elenko, president and co-founder of PureTech and acting CEO of Gallop Oncology. Times: 03:23 Kazia Therapeutics 31:56 PureTech Health PureTech Health PureTech Health plc is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming...

Listen to the Base to Base Biotech podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.